Natera’s Signatera MRD Test Lands on TIME’s Best Inventions of 2026…

Event summary

Natera’s Signatera MRD test named to TIME’s Best Inventions of 2026 in the Medical & Healthcare category.
Signatera is used by 55% of U.S. oncologists and supported by 200+ peer-reviewed publications.
Natera also named to Fortune’s Future 120 list in October 2026.
Signatera detects circulating tumor DNA (ctDNA) up to two years before imaging can.

The big picture

Natera’s inclusion in TIME’s Best Inventions and Fortune’s Future 120 underscores the growing validation of MRD testing in oncology. As precision medicine gains traction, Signatera’s ability to detect recurrence early positions Natera as a key player in reshaping cancer treatment strategies. The test’s role in clinical trials further strengthens its strategic value for both patients and pharmaceutical developers.

What we're watching

Adoption Dynamics: How Natera will leverage this recognition to accelerate Signatera’s adoption beyond the current 55% of U.S. oncologists.
Competitive Positioning: Whether Natera can sustain its leadership in MRD testing amid growing competition in precision oncology.
Regulatory Impact: The pace at which regulatory bodies may expand approvals for Signatera’s use in broader cancer care pathways.